Mitogen-activated protein kinase pathways in osteoblasts

Annual Review of Cell and Developmental Biology

Volumn 29, Issue , 2013, Pages 63-79

  Greenblatt, Matthew B ^a   Shim, Jae Hyuck ^b   Glimcher, Laurie H ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Department of Pathology and Laboratory Medicine ^*  (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AKT; bone mineralization; MAPK; RSK2; RUNX2

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; RSK2 KINASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

BONE MASS; BONE MINERALIZATION; CELL DIFFERENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BONE DEVELOPMENT; METABOLISM;

ANIMALS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOBLASTS; OSTEOGENESIS;

EID: 84884505578     PISSN: 10810706     EISSN: 15308995     Source Type: Book Series    
DOI: 10.1146/annurev-cellbio-101512-122347     Document Type: Review

References (98)

1. Zhang X, Lan W, Ems-McClung SC, Stukenberg PT, Walczak CE. 2007. Aurora B phosphorylates multiple sites on mitotic centromere-associated kinesin to spatially and temporally regulate its function. Mol. Biol. Cell 18:3264-76
2. Zhu C, Zhao J, Bibikova M, Leverson JD, Bossy-Wetzel E, et al. 2005. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol. Biol. Cell 16:3187-99
3. del Barco Barrantes I, Coya JM, Maina F, Arthur JS, Nebreda AR. 2011. Genetic analysis of specific and redundant roles for p38a and p38? MAPKs during mouse development. Proc. Natl. Acad. Sci. USA 108:12764-69
4. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, et al. 2005. Erk associates with and primes GSK-3 for its inactivation resulting in upregulation of -catenin. Mol. Cell 19:159-70
5. Dong C, Davis RJ, Flavell RA. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20:55-72
6. Eferl R,Hoebertz A, Schilling AF, Rath M, Karreth F, et al. 2004. The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 23:2789-99
7. Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, et al. 2006. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab. 4:441-51
8. Engin F, Yao Z, Yang T, Zhou G, Bertin T, et al. 2008. Dimorphic effects of Notch signaling in bone homeostasis. Nat. Med. 14:299-305
9. Ge C, Xiao G, Jiang D, Franceschi RT. 2007. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol. 176:709-18
10. Ge C, Xiao G, Jiang D, Yang Q, Hatch NE, et al. 2009. Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J. Biol. Chem. 284:32533-43
11. Ge C, Yang Q, Zhao G, Yu H, Kirkwood KL, Franceschi RT. 2011. Interactions between extracellular signal-regulated kinase 1/2 and P38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity. J. Bone Miner. Res. 27:538-51
12. Greenblatt MB, Shim JH, Zou W, Sitara D, Schweitzer M, et al. 2010. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J. Clin. Investig. 120:2457-73
13. Gupta S, Campbell D, Derijard B, Davis RJ. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267:389-93
14. Hai T, Curran T. 1991. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl. Acad. Sci. USA 88:3720-24
15. Hanauer A, Young ID. 2002. Coffin-Lowry syndrome: Clinical and molecular features. J. Med. Genet. 39:705-13
16. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, et al. 2008. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat. Med. 14:306-14
17. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere M-C, et al. 2005. Essential role of ?-catenin in postnatal bone acquisition. J. Biol. Chem. 280:21162-68
18. Hurd TW, Culbert AA, Webster KJ, Tavaré JM. 2002. Dual role formitogen-activated protein kinase (Erk) in insulin-dependent regulation of Fra-1 ( fos-related antigen-1) transcription and phosphorylation. Biochem. J. 368:573-80
19. Ishitani T, Hirao T, Suzuki M, Isoda M, Ishitani S, et al. 2010. Nemo-like kinase suppresses Notch signalling by interfering with formation of the Notch active transcriptional complex. Nat. Cell Biol. 12:278-85
20. IshitaniT,Ninomiya-Tsuji J,Nagai S, NishitaM,Meneghini M, et al. 1999. TheTAK1-NLK-MAPK-related pathway antagonizes signalling between ?-catenin and transcription factor TCF. Nature 399:798-802
21. Jochum W, David JP, Elliott C, Wutz A, Plenk H Jr, et al. 2000. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6:980-84
22. Junttila MR, Li SP, Westermarck J. 2008. Phosphatase-mediated crosstalk betweenMAPKsignaling pathways in the regulation of cell survival. FASEB J. 22:954-65
23. Kamakura S, Moriguchi T, Nishida E. 1999. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. 274:26563-71
24. Kanei-Ishii C, Ninomiya-Tsuji J, Tanikawa J, Nomura T, Ishitani T, et al. 2004. Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev. 18:816-29
25. Kawamata A, Izu Y, Yokoyama H, Amagasa T, Wagner EF, et al. 2008. JunD suppresses bone formation and contributes to low bone mass induced by estrogen depletion. J. Cell Biochem. 103:1037-45
26. Kenner L, Hoebertz A, Beil T, Keon N, Karreth F, et al. 2004. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J. Cell Biol. 164:613-23
27. Kolanczyk M, Kossler N, Kuhnisch J, Lavitas L, Stricker S, et al. 2007. Multiple roles for neurofibromin in skeletal development and growth. Hum. Mol. Genet. 16:874-86
28. Kortenjann M, Nehls M, Smith AJH, Carsetti R, Schüler J, et al. 2001. Abnormal bone marrow stroma in mice deficient for nemo-like kinase, Nlk. Eur. J. Immunol. 31:3580-87
29. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. 1999. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22:667-76
30. Li M, Liu J, Zhang C. 2011. Evolutionary history of the vertebrate mitogen activated protein kinases family. PLoS ONE 6:e26999
31. Li SP, Junttila MR, Han J, Kahari VM, Westermarck J. 2003. p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signalregulated kinase kinase1,2. Cancer Res. 63:3473-77
32. Li Y, Ge C, Franceschi RT. 2010. Differentiation-dependent association of phosphorylated extracellular signal-regulated kinase with the chromatin of osteoblast-related genes. J. Bone Miner. Res. 25:154-63
33. Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, et al. 2012. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med. 18:405-12
34. Manning AM, Davis RJ. 2003. Targeting JNK for therapeutic benefit: From junk to gold? Nat. Rev. Drug Discov. 2:554-65
35. Matsuo K, Owens JM, TonkoM, Elliott C, Chambers TJ, Wagner EF. 2000. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24:184-87
36. Matsushita T, Chan YY, Kawanami A, Balmes G, Landreth GE, Murakami S. 2009. Extracellular signalregulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell. Biol. 29:5843-57
37. Miyama K, Yamada G, Yamamoto TS ,Takagi C, Miyado K, et al. 1999. A BMP-inducible gene, dlx5, regulates osteoblast differentiation and mesoderm induction. Dev. Biol. 208:123-33
38. Moriguchi T, Kuroyanagi N, Yamaguchi K, Gotoh Y, Irie K, et al. 1996. A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J. Biol. Chem. 271:13675-79
39. Morrison DK, Davis RJ. 2003. Regulation ofMAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 19:91-118
40. Mundlos S, Otto F, Mundlos C,Mulliken JB, Aylsworth AS, et al. 1997. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89:773-79
41. Muniyappa H, Das KC. 2008. Activation of c-Jun N-terminal kinase ( JNK) by widely used specific p38MAPK inhibitors SB202190 and SB203580: A MLK-3-MKK7-dependent mechanism. Cell Signal. 20:675-83
42. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. 2002. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4:556-64
43. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, et al. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29
44. Nifuji A, Ideno H, Ohyama Y, Takanabe R, Araki R, et al. 2010. Nemo-like kinase (NLK) expression in osteoblastic cells and suppression of osteoblastic differentiation. Exp. Cell Res. 316:1127-36
45. Ohkawara B, Shirakabe K, Hyodo-Miura J,Matsuo R, Ueno N, et al. 2004. Role of the TAK1-NLK-STAT3 pathway in TGF-?-mediated mesoderm induction. Genes Dev. 18:381-86
46. Ortuño MJ, Ruiz-Gasp̀a S, Rodríguez-Carballo E, Susperregui AR, Bartrons R, et al. 2010. p38 regulates expression of osteoblast-specific genes by phosphorylation of osterix. J. Biol. Chem. 285:31985-94
47. Otto F, Thornell AP , Crompton T, Denzel A, Gilmour KC, et al. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-71
48. Pakay JL, Diesch J, Gilan O, Yip Y-Y, Sayan E, et al. 2012. A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells. Oncogene 31:1817-24
49. Pasteris NG, Cadle A, Logie LJ, Porteous ME, Schwartz CE, et al. 1994. Isolation and characterization of the faciogenital dysplasia (Aarskog-Scott syndrome) gene: A putative Rho/Rac guanine nucleotide exchange factor. Cell 79:669-78
50. Patterson KI, Brummer T, O?Brien PM, Daly RJ. 2009. Dual-specificity phosphatases: Critical regulators with diverse cellular targets. Biochem. J. 418:475-89
51. Pearce LR, Komander D, Alessi DR. 2010. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11:9-22
52. Pfarr CM, Mechta F, Spyrou G, Lallemand D, Carillo S, Yaniv M. 1994. Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell 76:747-60
53. Provot S, Nachtrab G, Paruch J, Chen AP, Silva A, Kronenberg HM. 2008. A-raf and B-raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes. Mol. Cell. Biol. 28:344-57
54. ReganCP, LiW,BoucherDM,Spatz S, SuMS, KuidaK. 2002. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc. Natl. Acad. Sci. USA 99:9248-53
55. Reimold AM, Grusby MJ, Kosaras B, Fries JW, Mori R, et al. 1996. Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice. Nature 379:262-65
56. Remy G, Risco AM, Iñesta-Vaquera FA, González-Terán B, Sabio G, et al. 2010. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal. 22:660-67
57. Rüther U, Garber C, Komitowski D, Müller R, Wagner EF. 1987. Deregulated c-fos expression interferes with normal bone development in transgenic mice. Nature 325:412-16
58. Ruther U, Komitowski D, Schubert FR,Wagner EF. 1989. c-fos expression induces bone tumors in transgenic mice. Oncogene 4:861-65
59. SakuraiH, Shigemori N, Hasegawa K, Sugita T. 1998. TGF-β-activated kinase 1 stimulates NF-κβactivation by an NF-κβ-inducing kinase-independent mechanism. Biochem. Biophys. Res. Commun. 243:545-49
60. Samee N, Geoffroy V, Marty C, Schiltz C, Vieux-Rochas M, et al. 2008. Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am. J. Pathol. 173:773-80
61. Schwartz CE, Gillessen-Kaesbach G, May M, Cappa M, Gorski J, et al. 2000. Two novel mutations confirm FGD1 is responsible for the Aarskog syndrome. Eur. J. Hum. Genet. 8:869-74
62. SeibenhenerML, Geetha T, Wooten MW. 2007. Sequestosome 1/p62-more than just a scaffold. FEBS Lett. 581:175-79
63. Shim J-H, GreenblattMB, Singh A, Brady N, Hu D, et al. 2011. Administration of BMP2/7 in utero partially reverses Rubinstein-Taybi syndrome-like skeletal defects induced by Pdk1 or Cbp mutations in mice. J. Clin. Investig. 122:91-106
64. Shim J-H, GreenblattMB, XieM, Schneider MD, Zou W, et al. 2009. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J. 28:2028-41
65. Shirakabe K, Yamaguchi K, Shibuya H, Irie K,Matsuda S, et al. 1997. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J. Biol. Chem. 272:8141-44
66. Sierra J, Villagra A, Paredes R, Cruzat F, Gutierrez S, et al. 2003. Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity. Mol. Cell. Biol. 23:3339-51
67. SilvaBC, Costa AG, Cusano NE,Kousteni S, Bilezikian JP. 2011. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J. Endocrinol. Investig. 34:801-10
68. Stevenson DA, Yan J, He Y, Li H, Liu Y, et al. 2011. Multiple increased osteoclast functions in individuals with neurofibromatosis type 1. Am. J. Med. Genet. A 155A:1050-59
69. Suzuki A, Palmer G, Bonjour JP, Caverzasio J. 1999. Regulation of alkaline phosphatase activity by p38 MAP kinase in response to activation of Gi protein-coupled receptors by epinephrine in osteoblast-like cells. Endocrinology 140:3177-82
70. Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, et al. 2007. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR- transactivation. Nat. Cell Biol. 9:1273-85
71. Takami M, Cho ES, Lee SY, Kamijo R, Yim M. 2005. Phosphodiesterase inhibitors stimulate osteoclast formation viaTRANCE/RANKLexpression in osteoblasts: possible involvement ofERKand p38MAPK pathways. FEBS Lett. 579:832-38
72. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, et al. 2008. Phosphorylation by p38 MAPK as an alternative pathway for GSK3 inactivation. Science 320:667-70
73. Thouverey C, Caverzasio J. 2012. The p38a MAPK positively regulates osteoblast function and postnatal bone acquisition. Cell. Mol. Life Sci. 69:3115-25
74. Ulsamer A, Ortuño MJ, Ruiz S, Susperregui AR, Osses N, et al. 2008. BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J. Biol. Chem. 283:3816-26
75. Ventura JJ, Kennedy NJ, Lamb JA, Flavell RA, Davis RJ. 2003. c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol. Cell. Biol. 23:2871-82
76. Vial E, Marshall CJ. 2003. Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci. 116:4957-63
77. Wan M, Cao X. 2005. BMP signaling in skeletal development. Biochem. Biophys. Res. Commun. 328:651-57
78. Wang W, Nyman JS, Ono K, Stevenson DA, Yang X, Elefteriou F. 2011. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum. Mol. Genet. 20:3910-24
79. Wang Z-Q, OvittC,Grigoriadis AE,Mohle-Steinlein U, RütherU,Wagner EF. 1992. Bone and haematopoietic defects in mice lacking c-fos. Nature 360:741-45
80. Whitehouse CA, Waters S, Marchbank K, Horner A, McGowan NW, et al. 2010. Neighbor of Brca1 gene (Nbr1) functions as a negative regulator of postnatal osteoblastic bone formation and p38 MAPK activity. Proc. Natl. Acad. Sci. USA 107:12913-18
81. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ. 1998. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281:1671-74
82. Wu X, Chen S, He Y, Rhodes SD, Mohammad KS, et al. 2011. The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1. PLoS ONE 6:e24917
83. Wu X, Tu X, Joeng KS, Hilton MJ,Williams DA, Long F. 2008. Rac1 activation controls nuclear localization of ?-catenin during canonical Wnt signaling. Cell 133:340-53
84. Xiao G, JiangD,GopalakrishnanR, FranceschiRT. 2002. Fibroblast growth factor 2 induction of the osteocalcin gene requiresMAPKactivity and phosphorylation of the osteoblast transcription factor,Cbfa1/Runx2. J. Biol. Chem. 277:36181-87
85. Xiao G, Jiang D, Thomas P, Benson MD, Guan K, et al. 2000. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J. Biol. Chem. 275:4453-59
86. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O?Brien CA. 2011. Matrix-embedded cells control osteoclast formation. Nat. Med. 17:1235-41
87. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, et al. 2008. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825-37
88. Yamashita M, Ying SX, Zhang GM, Li C, Cheng SY, et al. 2005. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 121:101-13
89. Yan L, Carr J, Ashby PR, Murry-Tait V, Thompson C, Arthur JS. 2003. Knockout of ERK5 causes multiple defects in placental and embryonic development. BMC Dev. Biol. 3:11
90. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, et al. 2004. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology: Implication for Coffin-Lowry Syndrome. Cell 117:387-98
91. Young MR, Nair R, Bucheimer N, Tulsian P, Brown N, et al. 2002. Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. Mol. Cell. Biol. 22:587-98
92. Yu X, Chen S, Potter OL, Murthy SM, Li J, et al. 2005. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 36:793-802
93. Zanotti S, Canalis E. 2012. Nemo-like kinase inhibits osteoblastogenesis by suppressing bone morphogenetic protein and WNT canonical signaling. J. Cell Biochem. 113:449-56
94. Zarubin T, Han J. 2005. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 15:11-18
95. Zhang Y, Zhong S, Dong Z, Chen N, Bode AM, Ma W. 2001. UVA induces Ser381 phosphorylation of p90RSK/MAPKAP-K1 via ERK and JNK pathways. J. Biol. Chem. 276:14572-80
96. Zheng Y, Fischer DJ, Santos MF, Tigyi G, Pasteris NG, et al. 1996. The faciogenital dysplasia gene product FGD1 functions as a Cdc42Hs-specific guanine-nucleotide exchange factor. J. Biol. Chem. 271:33169-72
97. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. 1999. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400:687-93
98. Zou W, GreenblattMB, Shim JH, Kant S, Zhai B, et al. 2011.MLK3regulates bone development downstream of the faciogenital dysplasia protein FGD1 in mice. J. Clin. Investig. 121:4383-92